Vicore Pharma Holding AB (VICO) Price & Analysis

Compare

3 Followers

VICO Stock Chart & Stats

kr11.08

-kr0.08(-1.06%)

At close: Mar 06 4:00 PM EST

kr11.08

-kr0.08(-1.06%)

Day’s Range― - ―

52-Week Rangekr6.09 - kr14.10

Previous CloseN/A

Volume158.42K

Average Volume (3M)520.11K

Market Cap

kr2.87B

Enterprise Valuekr1.81B

Total Cash (Recent Filing)kr1.17B

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.65

Next Earnings

May 06, 2026

EPS Estimate

-0.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding281,525,600

10 Day Avg. Volume692,423

30 Day Avg. Volume520,111

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)2.47

Price to Sales (P/S)710.16

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1.82

Revenue Forecast (FY)kr8.67M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetThe company reports essentially no debt and a materially expanded equity base, providing durable financial flexibility. Low leverage reduces refinancing and interest rate risk and supports continued funding of clinical programs over the next several months without immediate debt pressure.

Platform-focused R&DA concentrated AT2R platform and a clear lead candidate (C21) create a durable strategic focus. Platform specialization can accelerate learning across programs, enable indication expansion if clinical signals appear, and provide a clearer development path versus unfocused pipelines.

History Of Equity SupportMaterial equity expansion demonstrates the company has been able to access capital markets to fund operations. That track record of raising equity is a lasting offset to burn, indicating a near-term ability to secure financing without immediate reliance on debt markets.

Bears Say

Persistent Cash BurnOperating cash flow is persistently negative and worsened in 2025, creating a durable funding requirement. Continued cash burn increases dependence on external financing, risks dilution, and constrains the company’s ability to sustain multiple clinical programs without new capital.

Deteriorating Operating PerformanceRevenue volatility and a sharp decline in 2025, coupled with very large operating and net losses, indicate weakening operating fundamentals. This persistent deterioration undermines internal funding capacity, raises execution risk for trials, and lengthens the path to any self-sustaining operations.

Negative Returns On CapitalConsistently negative returns on equity reflect that deployed capital is not generating positive financial returns today. Over months this implies dilution risk, tougher future capital raises, and pressure on management to deliver clinical milestones to justify further investment.

Vicore Pharma Holding AB News

Vicore Pharma Strengthens Executive Ranks as Buloxibutid Nears Key Milestones

Vicore Pharma Holding AB ( ($SE:VICO) ) has issued an update. Vicore Pharma, a clinical-stage biopharma group specializing...

13h ago

Vicore Pharma Publishes Comprehensive Year-End 2025 Report

Vicore Pharma Holding AB ( ($SE:VICO) ) just unveiled an update. Vicore Pharma Holding AB has released its...

7d ago

Vicore Pharma Ramps Up Investor Outreach With Series of March Conferences

Vicore Pharma Holding AB ( ($SE:VICO) ) has issued an update. Vicore Pharma announced that its senior leadership...

8d ago

Vicore Pharma to Spotlight IPF Program at Oppenheimer Healthcare Conference

The latest update is out from Vicore Pharma Holding AB ( ($SE:VICO) ). Vicore Pharma will participate in...

16d ago

Vicore Pharma to Showcase IPF Program at J.P. Morgan Healthcare Conference

Vicore Pharma Holding AB ( ($SE:VICO) ) has issued an announcement. Vicore Pharma announced that its senior leadership...

2M ago

Vicore Pharma Upgraded to Nasdaq Stockholm Mid Cap Segment

An update from Vicore Pharma Holding AB ( ($SE:VICO) ) is now available. Vicore Pharma Holding AB will...

3M ago

Vicore Pharma to Participate in Rare Disease Summit

Vicore Pharma Holding AB ( ($SE:VICO) ) just unveiled an announcement. Vicore Pharma Holding AB announced its participation...

3M ago

Vicore Pharma Expands Share Capital with USD 48 Million Issue

Vicore Pharma Holding AB ( ($SE:VICO) ) has shared an update. Vicore Pharma Holding AB has announced an...

3M ago

Vicore Pharma to Present at Nordic Healthcare Conference

Vicore Pharma Holding AB ( ($SE:VICO) ) has provided an announcement. Vicore Pharma announced its participation in the...

4M ago

Vicore Pharma to Present at Jefferies Global Healthcare Conference

An announcement from Vicore Pharma Holding AB ( ($SE:VICO) ) is now available. Vicore Pharma announced its participation...

4M ago

VICO FAQ

What was Vicore Pharma Holding AB’s price range in the past 12 months?

Vicore Pharma Holding AB lowest stock price was kr6.09 and its highest was kr14.10 in the past 12 months.

What is Vicore Pharma Holding AB’s market cap?

Vicore Pharma Holding AB’s market cap is kr2.87B.

When is Vicore Pharma Holding AB’s upcoming earnings report date?

Vicore Pharma Holding AB’s upcoming earnings report date is May 06, 2026 which is in 62 days.

How were Vicore Pharma Holding AB’s earnings last quarter?

Vicore Pharma Holding AB released its earnings results on Feb 27, 2026. The company reported -kr0.54 earnings per share for the quarter, missing the consensus estimate of -kr0.455 by -kr0.085.

Is Vicore Pharma Holding AB overvalued?

According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vicore Pharma Holding AB pay dividends?

Vicore Pharma Holding AB does not currently pay dividends.

What is Vicore Pharma Holding AB’s EPS estimate?

Vicore Pharma Holding AB’s EPS estimate is -0.45.

How many shares outstanding does Vicore Pharma Holding AB have?

Vicore Pharma Holding AB has 281,525,600 shares outstanding.

What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?

Vicore Pharma Holding AB reported an EPS of -kr0.54 in its last earnings report, missing expectations of -kr0.455. Following the earnings report the stock price went down -2.896%.

Which hedge fund is a major shareholder of Vicore Pharma Holding AB?

Currently, no hedge funds are holding shares in SE:VICO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.